These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9875409)

  • 1. Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746.
    Franchetti P; Perlini P; Abu Sheikha G; Cappellacci L; Grifantini M; Loi AG; De Montis A; Pani A; Marongiu ME; La Colla P
    Antivir Chem Chemother; 1998 Jul; 9(4):303-9. PubMed ID: 9875409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus.
    Uckun FM; Pendergrass S; Qazi S; Samuel P; Venkatachalam TK
    Eur J Med Chem; 2004 Mar; 39(3):225-34. PubMed ID: 15051170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
    Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
    J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
    Holý A; Günter J; Dvoráková H; Masojídková M; Andrei G; Snoeck R; Balzarini J; De Clercq E
    J Med Chem; 1999 Jun; 42(12):2064-86. PubMed ID: 10377214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
    J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
    Mai A; Artico M; Sbardella G; Massa S; Novellino E; Greco G; Loi AG; Tramontano E; Marongiu ME; La Colla P
    J Med Chem; 1999 Feb; 42(4):619-27. PubMed ID: 10052969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
    Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
    Hocková D; Holý A; Masojídková M; Andrei G; Snoeck R; De Clercq E; Balzarini J
    J Med Chem; 2003 Nov; 46(23):5064-73. PubMed ID: 14584956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-(2,6-Dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1, 3-thiazolidin-4-ones: anti-HIV agents.
    Rawal RK; Tripathi R; Kulkarni S; Paranjape R; Katti SB; Pannecouque C; De Clercq E
    Chem Biol Drug Des; 2008 Aug; 72(2):147-54. PubMed ID: 18624810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
    Balani SK; Pitzenberger SM; Schwartz MS; Ramjit HG; Thompson WJ
    Drug Metab Dispos; 1995 Feb; 23(2):185-9. PubMed ID: 7736909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyanion inhibitors of human immunodeficiency virus and other viruses. 6. Micelle-like anti-HIV polyanionic compounds based on a carbohydrate core.
    Leydet A; Jeantet-Segonds C; Bouchitté C; Moullet C; Boyer B; Roque JP; Witvrouw M; Este J; Snoeck R; Andrei G; De Clercq E
    J Med Chem; 1997 Jan; 40(3):350-6. PubMed ID: 9022801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
    Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
    Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
    Chen P; Cheng PT; Alam M; Beyer BD; Bisacchi GS; Dejneka T; Evans AJ; Greytok JA; Hermsmeier MA; Humphreys WG; Jacobs GA; Kocy O; Lin PF; Lis KA; Marella MA; Ryono DE; Sheaffer AK; Spergel SH; Sun CQ; Tino JA; Vite G; Colonno RJ; Zahler R; Barrish JC
    J Med Chem; 1996 May; 39(10):1991-2007. PubMed ID: 8642558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent.
    Vig R; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1998 Sep; 9(5):445-8. PubMed ID: 9875398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.